Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk Relapsed/Refractory B Cell Non-Hodgkin Lymphoma(R/R B-NHL): A Multicenter, Prospective, Randomized, Open-label, Controlled Clinical Study

NCT06695013 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06695013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06695013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk Relapsed/Refractory B Cell Non-Hodgkin Lymphoma(R/R B-NHL): A Multicenter, Prospective, Randomized, Open-label, Controlled Clinical Study
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
March 20, 2027
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-nhl, cart therapy